NICE’s draft guidance has not recommended Lucentis for diabetic oedema after ‘faulty analysis’ from manufacturer Novartis was found not to …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

